BenevolentAI says second target identified by AstraZeneca collaborationProactive Investors • 06/25/24
AstraZeneca's lung cancer drug approved by US FDA for combination chemotherapy treatmentInvezz • 06/17/24
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancerBusiness Wire • 06/17/24
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancerReuters • 06/17/24
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven StocksInvestors Business Daily • 06/10/24
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancerBusiness Wire • 06/10/24
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins bigCNBC • 06/07/24
Nucleus RadioPharma Secures Series A Extension Funding with AstraZeneca InvestmentBusiness Wire • 06/05/24
Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030CNBC • 06/04/24
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024PRNewsWire • 06/04/24
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 06/03/24